Document is current
Any future updates will be listed below
-
Authors
Meloni, Bruno P.
Blacker, David J.
Edwards, Adam B.
Knuckey, Neville W.
-
Funding
Funding for this research was provided by:
University of Western Australia
- License Information
-
More Information
Article History
Accepted: 8 March 2022
First Online: 19 March 2022
Declarations
:
: BPM and NWK are the holders of several patents regarding the use of arginine-rich peptides as neuroprotective treatments. BPM, DJB, ABE and NWK are shareholders in Argenica Therapeutics, which is a company developing R18 and R18D as stroke therapeutics. In addition, DJB is a Clinical Advisor and BPM is the Chief Scientific Officer for Argenica Therapeutics.
: All animal work was performed in compliance with the Animal Ethics Committee of the University of Western Australia and following the guidelines outlined by the Australian Code for the Care and Use of Animals for Scientific Purposes and adhered to the Animal Welfare Act 2002 (Western Australia). Experimentation with human samples had the approval of the Perron Institute and consent of the one author (BM).
